Isoform-selective inhibition of phosphoinositide 3-kinase: Identification of a New Region of nonconserved amino acids critical for p110α inhibition

Molecular Pharmacology

Volumn 80, Issue 4, 2011, Pages 657-664

  Zheng, Zhaohua ^a   Amran, Syazwani I ^a   Thompson, Philip E ^a   Jennings, Ian G ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 5 NITRO 2 [(6 BROMOIMIDAZO[1,2 ALPHA]PYRIDIN 3 YL)METHYLENE] 1 METHYLHYDRAZIDE BENZENESULFONIC ACID; ADENOSINE TRIPHOSPHATE; ALANINE; AMINO ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE P110 ALPHA; PIK 75; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME BINDING; ENZYME INHIBITION; GENE MUTATION; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; WILD TYPE;

AMINO ACID SEQUENCE; AMINO ACIDS; ANIMALS; BINDING SITES; CELL LINE; CONSERVED SEQUENCE; ENZYME INHIBITORS; HYDRAZONES; INSECTS; ISOENZYMES; MOLECULAR SEQUENCE DATA; PHOSPHATIDYLINOSITOL 3-KINASES; SULFONAMIDES;

EID: 80053186835     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.072546     Document Type: Article

References (24)

1. Berndt A, Miller S, Williams O, Le DD, Houseman BT, Pacold JI, Gorrec F, Hon WC, Liu Y, Rommel C, et al. (2010) The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol 6:117-124.
2. Bowles DW and Jimeno A (2011) New phosphatidylinositol 3-kinase inhibitors for cancer. Expert Opin Investig Drugs 20:507-518.
3. Camps M, Rückle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Françon B, et al. (2005) Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 11:936-943. (Pubitemid 41294438)
4. Frazzetto M, Suphioglu C, Zhu J, Schmidt-Kittler O, Jennings IG, Cranmer SL, Jackson SP, Kinzler KW, Vogelstein B, and Thompson PE (2008) Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket. Biochem J 414:383-390.
5. Frederick R and Denny WA (2008) Phosphoinositide-3-kinases (PI3Ks): combined comparative modeling and 3D-QSAR to rationalize the inhibition of p110α. J Chem Inf Model 48:629-638. (Pubitemid 351535430)
6. Gabelli SB, Mandelker D, Schmidt-Kittler O, Vogelstein B, and Amzel LM (2010) Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design. Biochim Biophys Acta 1804:533-540.
7. Han M and Zhang JZ (2009) Class I phospho-inositide-3-kinases (PI3Ks) isoformspecific inhibition study by the combination of docking and molecular dynamics simulation. J Chem Inf Model 50:136-145.
8. Hayakawa M, Kaizawa H, Kawaguchi K, Ishikawa N, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, et al. (2007a) Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem 15:403-412. (Pubitemid 44738565)
9. Hayakawa M, Kawaguchi K, Kaizawa H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, et al. (2007b) Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem 15:5837-5844. (Pubitemid 47043472)
10. Huse M and Kuriyan J (2002) The conformational plasticity of protein kinases. Cell 109:275-282. (Pubitemid 34606870)
11. Johnson LN, Noble ME, and Owen DJ (1996) Active and inactive protein kinases: structural basis for regulation. Cell 85:149-158. (Pubitemid 26118158)
12. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, et al. (2006) A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125:733-747.
13. Kong D and Yamori T (2007) ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. Cancer Sci 98:1638-1642. (Pubitemid 47308463)
14. Li Y, Wang Y, and Zhang F (2010) Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110α inhibitors. Journal of Molecular Modeling 16:1449-1460.
15. Mandelker D, Gabelli SB, Schmidt-Kittler O, Zhu J, Cheong I, Huang CH, Kinzler KW, Vogelstein B, and Amzel LM (2009) A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane. Proc Natl Acad Sci USA 106:16996-17001.
16. Marone R, Cmiljanovic V, Giese B, and Wymann MP (2008) Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 1784:159-185.
17. Pirola L, Zvelebil MJ, Bulgarelli-Leva G, van Obberghen E, Waterfield MD, and Wymann MP (2001) Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha). Functions of lipid kinase-deficient PI3Kalpha in signaling. J Biol Chem 276:21544-21554.
18. Sabbah DA, Vennerstrom JL, and Zhong H (2010) Docking Studies on Isoform-Specific Inhibition of Phosphoinositide-3-Kinases. J Chem Inf Model 50:1887-1898.
19. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554. (Pubitemid 38541907)
20. Schmidt-Kittler O, Zhu J, Yang J, Liu G, Hendricks W, Lengauer C, Gabelli SB, Kinzler KW, Vogelstein B, Huso DL, et al. (2010) PI3Kα inhibitors that inhibit metastasis. Oncotarget 1:339-348.
21. Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss W, Shokat KM, and Stokoe D (2008) A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J 415:97-110.
22. vanhaesebroeck B, Guillermet-Guibert J, Graupera M, and Bilanges B (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11:329-341.
23. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, and Williams RL (2000) Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 6:909-919.
24. Workman P, Clarke PA, Raynaud FI, and van Montfort RL (2010) Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 70:2146-2157.